Holen Sie sich die Stockscreener-App
1.17
1.68%
-0.02
Handel nachbörslich:
1.18
0.01
+0.85%
Schlusskurs vom Vortag:
$1.19
Offen:
$1.22
24-Stunden-Volumen:
203.91K
Relative Volume:
0.38
Marktkapitalisierung:
$72.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-0.6359
EPS:
-1.84
Netto-Cashflow:
$-77.44M
1W Leistung:
-1.68%
1M Leistung:
-1.68%
6M Leistung:
-22.00%
1J Leistung:
-64.22%
1-Tages-Spanne:
$1.16
$1.22
1-Wochen-Bereich:
$1.11
$1.23
52-Wochen-Spanne:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie PYXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.17 | 73.72M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Financial Review: Ainos (NASDAQ:AIMD) vs. Pyxis Oncology (NASDAQ:PYXS) - Defense World
what makes pyxis oncology inc. stock price move sharplyGrowth Optimized Stock Radar - Newser
Why Pyxis Oncology Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser
How Pyxis Oncology Inc. stock performs during market volatilityDaily Trade Opportunity - Newser
What makes Pyxis Oncology Inc. stock price move sharplyDaily Volume Leaders - Newser
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Average Price Target from Analysts - Defense World
Pyxis Oncology (NASDAQ:PYXS) Stock Price Up 3.6% – Time to Buy? - Defense World
Pyxis Oncology Appoints New Principal Financial Officer - The Globe and Mail
Pyxis Oncology announces retirement of CFO and COO Pamela Connealy By Investing.com - Investing.com South Africa
Pyxis Oncology, Inc. Announces CFO Changes, Effective July 1, 2025 - MarketScreener
Pyxis Oncology's Equity Incentives: A Strategic Gambit for Clinical Success? - AInvest
Pyxis Oncology, Inc.(NasdaqGS: PYXS) dropped from Russell 3000 Index - MarketScreener
Pyxis Oncology, Inc.(NasdaqGS: PYXS) dropped from Russell 2000 Index - MarketScreener
Pyxis Oncology, Inc.(NasdaqGS: PYXS) dropped from Russell 2000 Dynamic Index - MarketScreener
Pyxis Oncology Inc (PYXS) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Pyxis Oncology shareholders elect three directors at annual meeting - Investing.com
Pyxis Oncology Elects New Directors at Annual Meeting - TipRanks
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ameriprise Financial Inc. Takes $35,000 Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Jane Street Group LLC Grows Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Nuveen Asset Management LLC Cuts Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Sold by Deutsche Bank AG - Defense World
ProShare Advisors LLC Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Northern Trust Corp Sells 15,449 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments - TipRanks
Millennium Management LLC Has $4.65 Million Stock Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Consensus PT from Analysts - Defense World
HC Wainwright Weighs in on Pyxis Oncology Q1 Earnings - Defense World
Q2 EPS Estimates for Pyxis Oncology Cut by HC Wainwright - Defense World
Leerink Partnrs Comments on Pyxis Oncology FY2029 Earnings - Defense World
Pyxis Oncology’s (PYXS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Pyxis Oncology (PYXS) Receives Reiterated Buy Rating from Analys - GuruFocus
Dimensional Fund Advisors LP Raises Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology : May 2025 Corporate Deck (9474da) - marketscreener.com
Pyxis Oncology Reports Q1 Loss and Business Update - TipRanks
Pyxis Oncology (PYXS) Advances Cancer Treatment Research | PYXS Stock News - GuruFocus
Pyxis Oncology, Inc. SEC 10-Q Report - TradingView
Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pyxis Oncology : May 2025 Corporate Deck (c8a9bd) - marketscreener.com
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 12,924 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology to Participate in Two Upcoming Investor Conferences - The Manila Times
Pyxis Oncology, Inc. CEO Lara S. Sullivan to Participate in Upcoming Investor Conferences - Nasdaq
Next-Gen Cancer Drug Developer Pyxis Oncology Sets Major Investor Conference Schedule for May-June - Stock Titan
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - Defense World
New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs - Baystreet.ca
Renaissance Technologies LLC Acquires 133,018 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):